CLINICAL_TRIALS
trial_result
· 2009-07-07
Clinical Trial Update: Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer [Phase 2]
Summary
Phase 2 trial of sorafenib as second-line therapy for advanced or metastatic gastric cancer has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Fudan University | Conditions: Gastric Cancer | Phase 2 | Status: TERMINATED